The UK’s National Institute for Health and Care Excellence has rejected several anticancer agents, and indicated that local clinical practice has still to be taken into account when introducing medicines – decisions which may act as a reality check to biotech and pharmaceutical companies.
The decisions include the rejection of the use of Merck & Co. Inc.’s Keytruda (pembrolizumab) as a first-line therapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?